Slide 1: Sustainability & P|ESG Report 2024
Exhibit 99.3 Sustainability & P|ESG Report 2024 www.ascendispharma.com
Slide 2: Environmental, Social and Governance Report Content
Patients|Environmental, Social and Governance Report (P|ESG) Content Introduction Introduction Progress 03 A message from our Executive Management Team 13 Patients 04 Our Business Model 18 Environmental P|ESG 05 A Brief History 22 Social Approach 07 2024 Sustainability & P|ESG Highlights 28 Governan
Slide 3: A message from our Executive Management Team
Introduction P|ESG Approach A message from our Executive Management Team At Ascendis Pharma, we remain dedicated to advancing our TransCon® technology platform as we continue to grow as a biopharmaceutical company with a clear focus on improving patients' lives. Guided by our values and vision, we a
Slide 4: Our Business Model
Our Business Model Ascendis Pharma was founded in 2007. We are support our research initiatives and clinical France, the UK, and the Nordic countries. Through applying our innovative TransCon platform to trials, and we use Contract Development and exclusive sales and distribution partners covering b
Slide 5: A Brief History
2007 A Brief History Ascendis Pharma is established. 2008 TransCon hGH is created. 2009 Transition from pre-clinical to clinical company. 2014 TransCon CNP is created. 2015 U.S. Nasdaq listing. TransCon PTH is created. 2018 Vision 2020 established. Strategic investment and exclusive license agreemen
Slide 6: Global Presence
Global Presence Introduction P|ESG Approach Progress Ambitions Strategic investment and Direct markets Exclusive distribution agreement exclusive license agreement Exclusive license agreement 6
Slide 7: 2024 Sustainability & P|ESG Highlights
2024 Sustainability & P|ESG Highlights In 2024, we conducted our pilot Double Materiality Assessment and continued improving our methodology in order to align our 2025 reporting with the material impacts, risks and opportunities identified. Introduction Patients Environmental • Launched Yorvipath in
Slide 8: Our Sustainability & P|ESG Approach
Our Sustainability & P|ESG Approach Our 2024 Sustainability & P|ESG reporting focuses on four key areas: Patients, Environmental, Social and Governance. It is designed to ensure our environmental and social license to operate through responsible governance practices, ultimately benefiting the busine
Slide 9: P|ESG Governance
P|ESG Governance Board of Directors Sustainability and P|ESG Reporting at Ascendis Pharma is guided by a governance structure that fosters a collaborative and integrated approach Introduction across the organization. The Ethics & Compliance Committee, including members of Executive Management, plays
Slide 10: Key Topics
Key Topics As part of our ongoing commitment to aligning our reporting with the priorities set out in the Ascendis strategy and by our stakeholders, this year we reassessed our key topics to confirm that they accurately reflect the most pressing issues to both our business and the patients we serve.
Slide 11: P|ESG Risks
Introduction P|ESG Risks As part of our business model, we are exposed to various environmental, social and governance (ESG) risks. Effectively P|ESG managing these risks, particularly those that could impact our Approach operations, helps us minimize business disruptions and protect the reputation
Slide 12: Risk Description, Risk Impact, Mitigating Actions
Risk Description Risk Impact Mitigating Actions At Ascendis Pharma, effective product innovation is central Ineffective innovation management may result in slower We foster product innovation through rigorous research and to our mission of addressing unmet medical needs. A development timelines and
Slide 13: Patients
Introduction Patients P|ESG Approach Progress Ambitions 13
Slide 14: Patients: Product Safety and Clinical Trial Diversity
At the core of our decision-making is our difficult due to the small numbers affected by Product Safety unwavering commitment to addressing the rare diseases. However, our work in this area has At Ascendis Pharma, we put patient safety unmet medical needs of patients. To this end, led us to expand r
Slide 15: Quality and Safety Policies; Access and Affordability
We adhere to the following quality and safety hypoparathyroidism, providing them with We have diligently augmented our resources to policies and procedures: access to potentially life-changing treatment. prepare for the seamless introduction of new In collaboration with the respective health product
Slide 16: Patient Support Program and Patient Engagement
transparency and respect for regulatory and The PSP provides patients with guidance on Follow-up on enrolled patients will continue industry standards. Every interaction with effectively and safely using our treatments, for up to an additional five years from the last patient organizations is ground
Slide 17: 2024 and 2025 Patient Reporting Ambitions
2024 and 2025 Sustainability and P|ESG Reporting Ambitions 2024 Ambitions Status Progress in 2024 2025 Ambitions Review the material impacts, Conduct a double materiality assessment We conducted a pilot Double Materiality risks and opportunities related Introduction to identify key patient prioritie
Slide 18: Environmental
Introduction Environmental P|ESG Approach Progress Ambitions 18
Slide 19: Climate Impact
At Ascendis Pharma, we recognize the Climate Impact importance of understanding and managing Our commitment to climate responsibility spans our environmental impact. While we do not across all our operations and the spaces we own manufacturing sites, we collaborate closely occupy. Our office and lab
Slide 20: Suppliers, Energy and GHG Emissions
Suppliers Energy Unit 2024 Contract Manufacturing Organizations (CMOs) and logistics providers are Energy Consumption vital to our business model, as we outsource all product manufacturing Total energy consumption MWh 5,780 activities. We expect our suppliers to meet the same standards we set for In
Slide 21: 2024 and 2025 Environmental Ambitions
2024 and 2025 Sustainability and P|ESG Reporting Ambitions 2024 Ambitions Status Progress in 2024 2025 Ambitions Validate and report on our Scope 1 & 2 We have successfully reported on our Scope Achieved greenhouse gas emissions data. 1 & 2 emissions data. Introduction Expand the collection of green
Slide 22: Social
Introduction Social P|ESG Approach Progress Ambitions 22
Slide 23: Employee Engagement & Development
In 2024, we recruited and onboarded more For further information and specific policies, We invite Ascendis Pharma employees to share than 300 new employees worldwide, reflecting kindly see our Code of Business Conduct & Ethics. their feedback through various surveys, including another year of substa
Slide 24: Corporate Diversity, Equity & Inclusion
strives for an equal representation of gender, Corporate Diversity, Equal Opportunity Corporate Diversity, Equity & Inclusion with an acceptable range of 40/60 split to either and Non-Discrimination Policy We are committed to building an inclusive gender in compliance with the guidelines issued work
Slide 25: Headcount, Health and Safety
Headcount 2021 2022 2023 2024 Selling, General and Administration* 236 305 354 492 Health and Safety R&D, Commercial Manufacturing 403 492 525 525 At Ascendis Pharma, we prioritize conducting business in a way that protects the health, safety, Total** 639 797 879 1,017 and well-being of our employee
Slide 26: People in our Value Chain and Human Rights
People in our Value Chain Human Rights Human Rights and Labor Rights Policy As outlined in the Environmental chapter, Our commitment to human rights is grounded in At Ascendis Pharma, we respect human rights our business relies on a network of suppliers internationally recognized standards, includin
Slide 27: 2024 and 2025 Social Ambitions
2024 and 2025 Sustainability and P|ESG Reporting Ambitions 2024 Ambitions Status Progress in 2024 2025 Ambitions Continued to enhance our global recruitment Introduction process to prioritize not only professional competencies but also team and culture fit. Attraction, onboarding and retention of ta
Slide 28: Governance
Introduction Governance P|ESG Approach Progress Ambitions 28
Slide 29: Business Conduct & Ethics and Compliance Program
At Ascendis Pharma, we are committed to associated policies and procedures. Any procedures aligned with these global minimum conducting our business in line with high ethical identified or potential breaches are subject to requirements while incorporating local-specific standards and in accordance w
Slide 30: Speak Up Policy & Whistleblower Hotline
Speak Up Policy & Whistleblower Hotline Our policy strictly prohibits retaliation against any Whistleblower Hotline Policy employee who, in good faith, seeks assistance or At Ascendis Pharma, we actively encourage reports suspected misconduct. The Whistleblower Hotline offers employees and expect ou
Slide 31: Anti-Corruption & Bribery Policy
established processes for reviewing external Anti-Corruption & -Bribery Policy Anti-Corruption & -Bribery medical and promotional materials prior to their As part of the Ascendis Pharma Compliance use. In 2024, these processes were updated to The Ascendis Pharma Anti-Corruption Program, all employee
Slide 32: Data Ethics Policy, Data Privacy and Governance
Data Ethics Policy Data Privacy Data Governance With the evolving landscape of data privacy laws Data Ethics We recognize the fact that our utilization of data, and regulations worldwide, we remain committed whether it is personal or non-personal, can As an innovative biopharma company focused to re
Slide 33: Animal Welfare
Ascendis Pharma further displayed the Animal Welfare commitment to animal welfare by signing Animal studies are required by regulatory the Marseille Declaration on the worldwide authorities and play an important role in the implementation of high standards for animals development of new pharmaceutic
Slide 34: 2024 and 2025 Governance Ambitions
2024 and 2025 Sustainability and P|ESG Reporting Ambitions 2024 Ambitions Status Progress in 2024 2025 Ambitions Continuous enhancement of our current third- party compliance approach as well as further In Carried out due diligence on sales and Introduction development of the due diligence process f
Slide 35: 2025 Sustainability & P|ESG Ambitions
2025 Sustainability & P|ESG Ambitions In 2025, we will further align our Sustainability & P|ESG framework to upcoming regulations by completing our Double Materiality Assessment to identify P|ESG impacts, risks and opportunities in our operations and value chain, and integrating our Sustainability S
Slide 36: Forward-looking statements
This report may contain forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, ob- jectives and expectations for our business operations and financial performance and condition, including with relation to our sustainability effor
Slide 37: Ascendis Pharma A/S contact details
Ascendis® Ascendis Pharma A/S (Company Reg. No. 29918791) Tuborg Boulevard 12 2900 Hellerup Denmark Tel: +45 70 22 22 44 Ascendis, Ascendis Pharma, Ascendis Pharma logo, the company logo, Skytrofa, Yorvipath, Ascendis Signature Access Program and TransCon are trademarks owned by the Ascendis Pharma